Benjamin Goodman

BENCH RESEARCH

Research Assistant, Portland State University, Portland, OR

Dec 2015 - Jul 2016

Independently investigated new methods of testing for pulmonary and systemic

carcinogens in electronic cigarettes and assisted in the evaluation of laboratory

samples using nuclear magnetic resonance

CLINICAL TRIALS

Sub-Investigator, Henry Ford Hospital, Detroit, MI

Oct 2023 - Jun 2025

Site Principal Investigator: Daniel R. Ouellette

A seamless, phase 1b/2 multiple ascending dose/proof of concept study of

XTMAB-16 in patients with pulmonary sarcoidosis with or without

extrapulmonary manifestations. Xentria, Inc. NCT05890729. Responsible for

chart review to identify patients who may be candidates for the study, obtaining

informed consent, physical exams, and obtaining medical history.

Sub-Investigator, Henry Ford Hospital, Detroit, MI

Mar 2023 - Jun 2025

Site Principal Investigator: Daniel R. Ouellette

A phase 3, randomized, double-blind, placebo-controlled study to evaluate the

efficacy and safety of intravenous efzofitimod in patients with pulmonary

sarcoidosis. aTyr Pharma, Inc. NCT05415137. Responsible for chart review to

identify patients who may be candidates for the study, obtaining informed

consent, physical exams, and obtaining medical history.

Sub-Investigator,Henry Ford Hospital, Detroit, MI
Sep 2022 - Jun 2023

Site Principal Investigator: Daniel R. Ouellette
A subject and investigator blinded, randomized, placebo-controlled, repeat-
dose, multicenter study to investigate efficacy, safety, and tolerability of CMK
389 in patients with chronic pulmonary sarcoidosis. Novartis. NCT04064242.
Responsible for chart review to identify patients who may be candidates for
the study.